ADME of Cancer

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/48

encourage image

There's no tags or description

Looks like no tags are added yet.

49 Terms

1
New cards
What two major properties must be balanced during anticancer drug development?
  • Pharmacodynamic properties (potency, selectivity and target activity) and pharmacokinetic properties (absorption, distribution, metabolism and excretion).

  • A drug must bind its target effectively and reach it at a sufficient concentration.


2
New cards
What are the main considerations when developing a new medicine?
  • Clinical benefit, safety, efficacy, patient tolerability, regulatory acceptability, commercial viability and affordability to healthcare services such as the NHS.


3
New cards
What is the difference between pharmacodynamics and pharmacokinetics?
  • Pharmacodynamics is what the drug does to the body, including target binding and therapeutic effects.

  • Pharmacokinetics is what the body does to the drug, including absorption, distribution, metabolism and excretion.


4
New cards
What is the difference between drug potency and selectivity?
  • Potency describes how much drug is required to produce an effect.

  • Selectivity describes how preferentially a drug acts at its intended target compared with other targets.


5
New cards
Why can a potent anticancer compound fail during drug development?
  • It may have poor aqueous solubility, inadequate absorption or bioavailability, rapid metabolism, inappropriate distribution or poor metabolic stability, preventing sufficient active drug from reaching the target.


6
New cards
What is first-pass metabolism, and why is it important for oral drugs?
Metabolism in the intestinal wall and liver before a drug reaches systemic circulation. It can reduce the amount of unchanged active drug reaching the circulation, lowering oral bioavailability.
7
New cards
Why is dose selection important in anticancer treatment?
The administered dose is not the same as the concentration reaching the target. Absorption, distribution, protein binding, metabolism and excretion affect exposure. Insufficient exposure may reduce efficacy, while excessive exposure increases toxicity.
8
New cards
What is the two-compartment pharmacokinetic model?
  • A simplified model with a central compartment representing blood/plasma and a peripheral compartment representing tissues.


9
New cards
How does plasma protein binding affect drug distribution?
  • Only unbound drug can directly distribute into tissues. Protein-bound drug acts as a reservoir that can release free drug as equilibrium changes.


10
New cards

What is volume of distribution (Vd)?

What does a larger Vd indicate?

  • The apparent volume relating the total amount of drug in the body to its plasma concentration.

  • A larger Vd generally indicates more extensive distribution outside plasma


11
New cards
How do oral and intravenous administration differ pharmacokinetically?
  • Oral drugs require gastrointestinal dissolution and absorption and may undergo first-pass metabolism.

  • IV drugs enter systemic circulation directly, avoiding the absorption step and initial first-pass metabolism.


12
New cards
What is bioavailability?
  • The fraction of an administered dose reaching systemic circulation unchanged


13
New cards
What is a structure–activity relationship (SAR)?
  • The relationship between a molecule's chemical structure and its biological activity. Structural modifications are tested to optimise potency, target binding and selectivity.


14
New cards
What is a structure–property relationship (SPR)?
  • The relationship between chemical structure and physicochemical or pharmacokinetic properties


15
New cards
Which pharmacokinetic properties are considered during SPR optimisation?
  • Aqueous solubility, membrane permeability, lipophilicity, pKa, chemical/metabolic stability, metabolite formation, CYP450 inhibition, plasma protein binding and volume of distribution.


16
New cards
What are the main non-covalent interactions involved in drug–target binding?
  • Ionic interactions between oppositely charged groups (long-range);

  • H-bonds between suitable donors and acceptors (intermediate-range);

  • van der Waals interactions between closely positioned atoms (short-range).


17
New cards
Which amino-acid side chains commonly participate in hydrophobic, hydrogen-bonding and ionic interactions?


18
New cards

What N functional groups are not normal Hydrogen bond acceptors?


  • Amide nitrogen and protonated amines are not normally acceptors.


19
New cards
What is the pharmacodynamic mechanism illustrated by the gefitinib precursor?
  • It competes with ATP at a kinase binding site and forms specific interactions, including hydrogen bonds, that inhibit kinase activity.



20
New cards
How was gefitinib optimised to improve its pharmacokinetic properties?
  • Modification of a hydrophobic region helped reduce metabolic susceptibility,

  • modification of a solvent-exposed region improved solubility without substantially disrupting essential kinase-binding interactions.


21
New cards
How do ATP-competitive kinase inhibitors reduce abnormal growth signalling?
  • They occupy the kinase ATP-binding site, interfering with ATP-dependent phosphorylation of substrates, reducing downstream signalling that promotes cell proliferation or survival.


22
New cards
What is Bcr-Abl, and how does imatinib act on it?
  • Bcr-Abl is an oncogenic protein kinase that promotes abnormal growth signalling.

  • Imatinib inhibits its kinase activity by binding in the ATP-binding region, preventing normal phosphorylation signalling.


23
New cards
Why is kinase selectivity important, and which targets are highlighted for imatinib?
  • Related kinases have similar ATP-binding sites, so inhibitors may act on multiple enzymes.


24
New cards

What are the mechanisms and targets of paclitaxel and methotrexate?

  • Paclitaxel is a spindle poison that binds tubulin and disrupts mitosis.

  • Methotrexate is an antimetabolite that inhibits dihydrofolate reductase (DHFR).


25
New cards
What are Lipinski's Rule of Five criteria?
  • No more than 5 hydrogen-bond donors

  • No more than 10 hydrogen-bond acceptors

  • MW below 500 Da

  • LogP below 5


26
New cards
How can basic functional groups be used to form water-soluble drug salts?
  • Primary, secondary or tertiary amines can be protonated using an acid such as HCl, producing a charged ammonium salt that may improve aqueous solubility.


27
New cards
How can acidic functional groups be used to form water-soluble drug salts?
  • Acidic groups such as carboxylic acids, suitable sulfonamides and tetrazoles can be deprotonated using an appropriate base, forming ionic salts such as sodium salts.


28
New cards
What two requirements must be met for successful oral absorption?
  • First, the drug must dissolve in aqueous gastrointestinal fluid, generally favoured by ionisation.

  • Second, it must cross the lipid gastrointestinal membrane, generally favoured for passive diffusion by the non-ionised lipophilic form.


29
New cards

How can poorly soluble drugs be formulated for intravenous administration?

What is an example

  • They must be suitably solubilised, potentially through salt formation, co-solvents or solubilising agents.

  • Paclitaxel is an example requiring solubilising agents or co-solvents for IV admin


30
New cards
Why was chlormethine unsuitable for oral administration in the lecture's example?

Chlormethine is a highly reactive nitrogen mustard that reacts readily with nucleophiles, creating toxicity concerns when administered orally.


31
New cards
Explain the chemical mechanism of nitrogen mustard alkylation.
  • The nitrogen lone pair attacks an adjacent chloroethyl carbon intramolecularly, displacing chloride and forming a reactive aziridinium ion.

  • A nucleophile such as DNA guanine N7 attacks the aziridinium ring, opening it and forming a covalent bond.

  • The second chloroethyl group can react similarly, producing further alkylation and possible DNA cross-linking.


32
New cards
How do nitrogen mustard alkylating agents cause cancer cell death?
  • They alkylate DNA, commonly at guanine N7, causing abnormal base pairing, cross-linking and DNA damage.

  • This interferes with DNA synthesis and can trigger cell death. Their action is described as cell-cycle non-specific.


33
New cards

How does attaching a nitrogen mustard to an aromatic ring reduce reactivity?

But what does adding an aromatic ring do?

How can we fix this?

  • The nitrogen lone pair becomes less available because it can delocalise into the aromatic ring.

  • This reduces aziridinium ion formation and lowers chemical reactivity.

knowt flashcard image
  • reduces aqueous solubility

  • introduce polarity/salt forming groups to improve solubility



<ul><li><p>The nitrogen lone pair becomes less available because it can delocalise into the aromatic ring.</p></li><li><p> This reduces aziridinium ion formation and lowers chemical reactivity.</p></li></ul><img src="https://assets.knowt.com/user-attachments/081cdee8-3f6b-41d9-a194-bfce093e0936.png" data-width="50%" data-align="center" alt="knowt flashcard image" style="display: block; width: 50%; margin-left: auto; margin-right: auto;"><ul><li><p>reduces aqueous solubility</p></li><li><p>introduce polarity/salt forming groups to improve solubility</p><ul><li><p></p><img src="https://assets.knowt.com/user-attachments/dd6de9ad-4f51-44d8-b1ea-d4764632b942.png" data-width="50%" data-align="center" style="display: block; width: 50%; margin-left: auto; margin-right: auto;"></li></ul></li></ul><p></p>
34
New cards
How do melphalan and chlorambucil demonstrate optimisation of nitrogen mustards?
  • Both retain an aromatic nitrogen mustard to reduce reactivity.

  • Melphalan contains amino and carboxylic acid groups

  • Chlorambucil contains a carboxylic acid group.

    • These provide polarity and opportunities for ionisation or salt formation.



35
New cards
How does tamoxifen reduce proliferation in oestrogen-dependent breast cancer?
  • Oestradiol stimulates oestrogen receptors on susceptible tumour cells, promoting proliferation.

  • Tamoxifen competes for the receptor-binding site, reducing oestrogen-driven signalling, proliferation and tumour growth.


36
New cards
What is the significance of tamoxifen metabolism in the lecture?
  • Tamoxifen undergoes CYP-mediated metabolism, with CYP2D6 and CYP3A4 highlighted, producing active hydroxylated metabolites including 4-hydroxytamoxifen.


37
New cards

What is name of active metabolite of tamoxifen?

  • 4-hydroxytamoxifen


38
New cards
Why can the active metabolite of tamoxifen compete with oestradiol for receptor binding?
  • occupy similar positions within the oestrogen receptor pocket, allowing favourable interactions despite having a different chemical structure


39
New cards
How can the solubility of an antioestrogen be improved without impairing receptor binding?
  • Preserve the lipophilic region needed for receptor interactions and introduce a basic, salt-forming group in a solvent-exposed region.

  • Hydrochloride salt formation improves aqueous solubility while maintaining pharmacodynamic activity.



40
New cards
What is the mechanism of action of camptothecin?
  • Camptothecin inhibits topoisomerase I, interfering with the enzyme's role in controlling DNA topology during replication and transcription.


41
New cards
Why does camptothecin have poor aqueous solubility?
  • It has no convenient salt-forming groups, and its planar aromatic structure promotes stacking in the solid state, making it difficult for solvent molecules to penetrate and dissolve the compound.


42
New cards
Why did opening camptothecin's lactone ring fail as a drug-development strategy?
  • intact lactone ring is essential for interaction with the topoisomerase I–DNA complex. Ring opening therefore destroyed pharmacodynamic activity.


43
New cards

How does topotecan overcome camptothecin's solubility problem (lactone ring)?

How can topotecan be administered?

  • Topotecan contains a solvent-exposed tertiary aliphatic amine that can form a water-soluble hydrochloride salt, while retaining the intact lactone ring needed for topoisomerase I inhibition.


  • It can be administered orally or intravenously.


44
New cards

What can topotecan be used to treat?

Treatment of small-cell lung cancer.
45
New cards

Why are fluorine and chlorine introduced during medicinal chemistry optimisation?

What problem with adding too many halogens?

  • They can block metabolically susceptible positions and reduce CYP-mediated oxidation, improving metabolic stability and potentially extending half-life.

  • However, they may also increase lipophilicity and affect solubility or target binding.


46
New cards

How does fluorine substitution improve the metabolic stability of crizotinib?

  • A benzene-ring position susceptible to CYP450 aromatic hydroxylation is substituted with fluorine, reducing metabolism while making a relatively small steric change.


  • Crizotinib is an ALK inhibitor used in non-small-cell lung cancer.


47
New cards

How does CF₃ substitution reduce metabolism in sorafenib?

  • A methyl group susceptible to CYP450-mediated aliphatic hydroxylation is replaced with a trifluoromethyl group, reducing that metabolic transformation.


  • Sorafenib is presented as a RAF kinase inhibitor used in advanced renal carcinoma.


48
New cards
How does CF₃ substitution reduce metabolism in sonidegib?
  • A metabolically susceptible methyl ether group is modified using CF₃ substitution to reduce CYP450-mediated O-dealkylation.


  • Sonidegib is a Hedgehog pathway inhibitor used in basal cell carcinoma.


49
New cards
Which structural features of abemaciclib illustrate simultaneous optimisation of potency and ADME?
A hinge-binding motif supports kinase target binding, a metabolism-blocking substituent improves metabolic stability, and a solvent-exposed piperazine group contributes to aqueous solubility. The lecture associates abemaciclib with metastatic breast cancer.